PDCD1 and lung cancer: In the past decade, immunotherapies, especially targeting the prominent immune checkpoints like anti-programmed cell death protein 1 (anti-PD-1) and anti-CTLA-4, have attracted growing attention since they showed unprecedented efficacy in a variety of cancer types, such as melanoma, breast cancer, lung cancer, and liver cancer [8, 9].